<p>儘管投資者經常忽視 <strong>道瓊斯工業平均指數</strong>，更青睞 <strong>標普 500 指數</strong> 和 <strong>納斯達克 100 指數</strong>，但道瓊斯包含了一些世界上質量最高的企業。要購買的頂級道瓊斯股票代表了廣泛的行業範圍，以其穩定性、韌性和潛力穩定增長而聞名。</p>
<p>與更具波動性的科技重點指數不同，道瓊斯的成分往往是具有良好業績記錄的老牌公司。這使得道瓊斯股票成為投資者生成股票投資理念的絕佳起點，尤其是那些新手投資者，希望將他們的前幾千美元投入運作。</p>
<p>鑑於我已將大多數道瓊斯成分視為高質量企業，我選擇購買道瓊斯股票的標準是專注於識別相對於增長前景而言定價最具吸引力的道瓊斯股票。鑑於包括道瓊斯在內的廣泛指數最近已經錄得實質性收益，尋找價格合理的股票以確保合理的安全邊際至關重要。以下三個股票提供了出色的價值、質量和增長潛力。</p>
<h2>麥當勞（MCD）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>來源：Tama2u / Shutterstock</p>
<p>在我看來，如今道瓊斯成分中最具吸引力的投資機會是 <strong>麥當勞</strong>（紐約證券交易所：<strong>MCD</strong>）。作為快餐服務領域中最重要的參與者，在全球擁有超過 41,000 家門店，其股價在 2024 年下跌約 12.5%，表現不及道瓊斯和整體市場。股價下跌可以歸因於市場對支付能力危機的定價，因為即使快餐似乎也變得相當昂貴，食品成本和勞動力成本最近大幅上漲。</p>
<p>儘管這些擔憂是合理的，麥當勞的運營結果仍然相當穩健。儘管在公司最近的第一季度報告中，同店銷售僅增長了 1.9%，這一時期標誌着連續第 13 個季度實現同店銷售增長。麥當勞尋常中等單數字增長率的短期停滯是可以理解的。事實上，同店銷售沒有下滑，並且繼續從已經較高水平增長是令人印象深刻的。</p>
<p>與此同時，麥當勞股票目前僅以今年預期每股收益的 21 倍交易，低於其歷史平均水平。我認為這一倍數提供了顯著的安全邊際和有意義的上行潛力，特別是考慮到華爾街預計麥當勞的每股收益增長將在中期加速至高個位數到低兩位數。</p>
<h2>強生（JNJ）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>來源：Alexander Tolstykh / Shutterstock.com</p>
<p>道瓊斯中另一個值得考慮購買的引人注目投資機會是 <strong>強生</strong>（紐約證券交易所：<strong>JNJ</strong>）。作為全球最大和最多元化的醫療保健巨頭之一，強生股票很少以折扣價交易。投資者歷來願意為公司股份支付溢價，因為公司擁有眾多優點，包括其長達 49 年的股息增長記錄。</p>
<p>鑑於強生在投資者中贏得的傳奇聲譽，無論您是首次投資 1000 美元還是向投資組合再增加 1000 美元，它都是一個出色選擇。這支股票幾十年來一直表現良好，我認為這一趨勢不會很快改變。</p>
<p>每當您可以以折扣價購買股票時，就像目前公司以僅 14 倍的前瞻市盈率交易一樣，明顯低於其約 17 倍至 18 倍的歷史平均水平，利用折扣是明智的。</p>
<p>與此同時，強生的整體增長仍然相當強勁。公司在第一季度將其調整後的每股收益提高了 12.4%，而共識預測看到中期持續的每股收益增長率在中等單數字水平。鑑於公司傾向於超越分析師預期，這些數字進一步説明了為什麼股票當前的估值相當有吸引力。</p>
<h2>美國聯合健康集團（UNH）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>來源：Ken Wolter / Shutterstock.com</p>
<p>我將這份清單以 <strong>美國聯合健康集團</strong>（紐約證券交易所：<strong>UNH</strong>）結束，這是道瓊斯中另一個值得考慮購買的落後者。2024 年 UNH 股價下跌約 11%，UNH 股票落後於其指數同行。儘管如此，UNH 股票也是一家很少以折價估值交易的公司，因此任何這樣的股價滯後都是值得研究的潛在機會。</p>
<p>這似乎是情況，UNH 股票現在以非常有吸引力的估值交易，儘管其強勁的增長前景。在其第一季度業績中，UNH 的營收增長了近 9%，達到 998 億美元。其調整後的每股收益也增長了 10.4%，達到 6.91 美元，公司錄得調整後的營運利潤率擴張和股份回購，進一步促進了這一數字的增長。這一上下線增長與 UNH 的歷史趨勢相匹配，表明持續增長且沒有放緩的跡象。</p>
<p>隨着 UNH 的增長保持強勁，股價滯後，股票的估值已經壓縮至相當有吸引力的水平。以今年預期調整後每股收益的 17.4 倍交易，我相信 UNH 股票提供了安全性和上行潛力的強大組合，特別是隨着雙位數盈利增長的持續。隨着 P/E 擴張可能增加未來回報前景，UNH 股票絕對是值得您下一個 1000 美元投資的股票。</p>
<p><em>在發佈日期，Nikolaos Sismanis 沒有持有（直接或間接）本文提到的證券中的任何頭寸。本文中表達的觀點屬於作者，遵守 InvestorPlace.com 的發佈準則。</em></p>
<p>Nikolaos Sismanis 是一位專業的研究分析師，在股票研究和財務建模領域擁有五年的經驗。Nikolaos 撰寫了超過 1,000 篇與股票相關的文章，專注於發掘深度價值機會，識別合理估值的成長股，並關注被忽視的國際股票。</p>

麥當勞

聯合健康

外服控股

強生

<p>道瓊斯工業平均指數包括具有穩定性、韌性和增長潛力的高質量企業。麥當勞、強生和聯合健康集團是三隻值得考慮投資的道瓊斯股票。麥當勞具有顯著的安全邊際和上行潛力，而強生正在以折扣價交易，並具有強勁的整體增長。聯合健康集團在道瓊斯指數中表現較差，但也呈現投資機會</p>

<p>While investors often overlook the <strong>Dow Jones Industrial Average</strong> in favor of the <strong>S&amp;P 500</strong> and the <strong>Nasdaq 100</strong>, the Dow comprises some of the highest-quality businesses in the world. The top Dow stocks to buy represent a broad spectrum of industries and are known for their stability, resilience, and potential for steady growth.</p>
<div class="lb-trans"><p>儘管投資者經常忽視 <strong>道瓊斯工業平均指數</strong>，更青睞 <strong>標普 500 指數</strong> 和 <strong>納斯達克 100 指數</strong>，但道瓊斯包含了一些世界上質量最高的企業。要購買的頂級道瓊斯股票代表了廣泛的行業範圍，以其穩定性、韌性和潛力穩定增長而聞名。</p>
</div><p>Unlike the more volatile tech-heavy indices, the Dow’s components tend to be established firms with strong track records. This makes Dow stocks to buy as an excellent starting point for investors to generate stock ideas, especially those new to the market and looking to put their first few thousand dollars to work.</p>
<div class="lb-trans"><p>與更具波動性的科技重點指數不同，道瓊斯的成分往往是具有良好業績記錄的老牌公司。這使得道瓊斯股票成為投資者生成股票投資理念的絕佳起點，尤其是那些新手投資者，希望將他們的前幾千美元投入運作。</p>
</div><p>Given that I already regard most Dow components as high-quality businesses, my criteria for selecting Dow stocks to buy focused on identifying the most attractively priced Dow stocks relative to their growth prospects. With broad indices, including the Dow, having already recorded substantial gains lately, it’s essential to seek out reasonably priced stocks to ensure a decent margin of safety. The following three names offer an excellent blend of value, quality, and growth potential.</p>
<div class="lb-trans"><p>鑑於我已將大多數道瓊斯成分視為高質量企業，我選擇購買道瓊斯股票的標準是專注於識別相對於增長前景而言定價最具吸引力的道瓊斯股票。鑑於包括道瓊斯在內的廣泛指數最近已經錄得實質性收益，尋找價格合理的股票以確保合理的安全邊際至關重要。以下三個股票提供了出色的價值、質量和增長潛力。</p>
</div><h2>McDonald’s (MCD)</h2>
<div class="lb-trans"><h2>麥當勞（MCD）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Tama2u / Shutterstock</p>
<div class="lb-trans"><p>來源：Tama2u / Shutterstock</p>
</div><p>In my view, the most compelling investment opportunity amongst the Dow Jones components today is <strong>McDonald’s</strong> (NYSE:<strong>MCD</strong>). The most prominent player in the quick-service restaurant space, boasting over 41,000 locations worldwide, has seen its shares decline by about 12.5% in 2024, underperforming the Dow Jones and the overall market. The stock’s decline can be attributed to the market pricing in an affordability crisis, as even fast food seems rather expensive these days, with the cost of food ingredients and labor having surged lately.</p>
<div class="lb-trans"><p>在我看來，如今道瓊斯成分中最具吸引力的投資機會是 <strong>麥當勞</strong>（紐約證券交易所：<strong>MCD</strong>）。作為快餐服務領域中最重要的參與者，在全球擁有超過 41,000 家門店，其股價在 2024 年下跌約 12.5%，表現不及道瓊斯和整體市場。股價下跌可以歸因於市場對支付能力危機的定價，因為即使快餐似乎也變得相當昂貴，食品成本和勞動力成本最近大幅上漲。</p>
</div><p>While these concerns are valid, McDonald’s operating results remain largely resilient. Despite a modest slowdown, with same-store sales rising by just 1.9% in the company’s most recent Q1 report, this period marked the 13th consecutive quarter of positive same-store sales growth. A short-term halt from McDonald’s usual mid-single-digit growth rates is understandable. If anything, the fact that same-store sales haven’t dipped and continue to grow from already high levels is impressive.</p>
<div class="lb-trans"><p>儘管這些擔憂是合理的，麥當勞的運營結果仍然相當穩健。儘管在公司最近的第一季度報告中，同店銷售僅增長了 1.9%，這一時期標誌着連續第 13 個季度實現同店銷售增長。麥當勞尋常中等單數字增長率的短期停滯是可以理解的。事實上，同店銷售沒有下滑，並且繼續從已經較高水平增長是令人印象深刻的。</p>
</div><p>In the meantime, following its recent dip, McDonald’s stock trades at just 21x this year’s expected earnings per share, below its historical average. I think this multiple presents a notable margin of safety and potential for meaningful upside, especially considering Wall Street expects McDonald’s EPS growth to accelerate in the high single digits to low double digits over the medium term.</p>
<div class="lb-trans"><p>與此同時，麥當勞股票目前僅以今年預期每股收益的 21 倍交易，低於其歷史平均水平。我認為這一倍數提供了顯著的安全邊際和有意義的上行潛力，特別是考慮到華爾街預計麥當勞的每股收益增長將在中期加速至高個位數到低兩位數。</p>
</div><h2>Johnson &amp; Johnson (JNJ)</h2>
<div class="lb-trans"><h2>強生（JNJ）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Alexander Tolstykh / Shutterstock.com</p>
<div class="lb-trans"><p>來源：Alexander Tolstykh / Shutterstock.com</p>
</div><p>Another compelling investment opportunity within the Dow to consider buying following its drop in the past year is <strong>Johnson &amp; Johnson</strong> (NYSE: <strong>JNJ</strong>). As one of the largest and most diversified healthcare giants globally, Johnson &amp; Johnson stock rarely trades at a discount. Investors have historically been willing to pay a premium for a stake in the company due to its numerous qualities, including its 49-year dividend growth track record.</p>
<div class="lb-trans"><p>道瓊斯中另一個值得考慮購買的引人注目投資機會是 <strong>強生</strong>（紐約證券交易所：<strong>JNJ</strong>）。作為全球最大和最多元化的醫療保健巨頭之一，強生股票很少以折扣價交易。投資者歷來願意為公司股份支付溢價，因為公司擁有眾多優點，包括其長達 49 年的股息增長記錄。</p>
</div><p>Given the legendary reputation Johnson &amp; Johnson has earned among investors, it stands out as an excellent choice, whether you are making your first $1,000 investment or adding another $1,000 to your portfolio. The stock has consistently performed well for decades, and I don’t see this trend changing anytime soon.</p>
<div class="lb-trans"><p>鑑於強生在投資者中贏得的傳奇聲譽，無論您是首次投資 1000 美元還是向投資組合再增加 1000 美元，它都是一個出色選擇。這支股票幾十年來一直表現良好，我認為這一趨勢不會很快改變。</p>
</div><p>Whenever you can buy shares at a discount, as is currently the case with the company trading at a forward price to earnings (P/E) ratio of just 14x, notably below its historical average of around 17x to 18x, it is wise to take advantage of the discount.</p>
<div class="lb-trans"><p>每當您可以以折扣價購買股票時，就像目前公司以僅 14 倍的前瞻市盈率交易一樣，明顯低於其約 17 倍至 18 倍的歷史平均水平，利用折扣是明智的。</p>
</div><p>In the meantime, Johnson &amp; Johnson’s overall growth remains quite strong. The company increased its adjusted EPS by 12.4% in Q1, while consensus estimates see sustained EPS growth in the mid-single digits over the medium term. Given the company’s tendency to beat analyst estimates, these numbers further expose why the stock’s current valuation is rather attractive.</p>
<div class="lb-trans"><p>與此同時，強生的整體增長仍然相當強勁。公司在第一季度將其調整後的每股收益提高了 12.4%，而共識預測看到中期持續的每股收益增長率在中等單數字水平。鑑於公司傾向於超越分析師預期，這些數字進一步説明了為什麼股票當前的估值相當有吸引力。</p>
</div><h2>UnitedHealth Group (UNH)</h2>
<div class="lb-trans"><h2>美國聯合健康集團（UNH）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Ken Wolter / Shutterstock.com</p>
<div class="lb-trans"><p>來源：Ken Wolter / Shutterstock.com</p>
</div><p>I will wrap this list with <strong>UnitedHealth Group</strong>(NYSE:<strong>UNH</strong>), another laggard within the Dow worth considering. Shares are down roughly 11% in 2024, with UNH stock falling considerably behind its index peers. Still, UNH stock is also a name that rarely trades at a discounted valuation, so any such share price lags are potential opportunities worth examining.</p>
<div class="lb-trans"><p>我將這份清單以 <strong>美國聯合健康集團</strong>（紐約證券交易所：<strong>UNH</strong>）結束，這是道瓊斯中另一個值得考慮購買的落後者。2024 年 UNH 股價下跌約 11%，UNH 股票落後於其指數同行。儘管如此，UNH 股票也是一家很少以折價估值交易的公司，因此任何這樣的股價滯後都是值得研究的潛在機會。</p>
</div><p>This seems to be the case, with UNH stock now trading at a highly compelling valuation despite its robust growth prospects. In its Q1 results, UNH grew revenues by nearly 9% to $99.8 billion. Its adjusted EPS also grew by a notable 10.4% to $6.91, with the company recording an adjusted operating margin expansion and share repurchases, further aiding the growth of this figure. This top and bottom line growth matches UNH’s historical trends, suggesting sustained growth with no signs of a slowdown.</p>
<div class="lb-trans"><p>這似乎是情況，UNH 股票現在以非常有吸引力的估值交易，儘管其強勁的增長前景。在其第一季度業績中，UNH 的營收增長了近 9%，達到 998 億美元。其調整後的每股收益也增長了 10.4%，達到 6.91 美元，公司錄得調整後的營運利潤率擴張和股份回購，進一步促進了這一數字的增長。這一上下線增長與 UNH 的歷史趨勢相匹配，表明持續增長且沒有放緩的跡象。</p>
</div><p>With UNH’s growth remaining robust against a lagging share price, the stock has compressed its valuation to rather attractive levels. At 17.4x this year’s expected adjusted EPS, I believe that UNH stock provides a potent mix of safety and upside, particularly with double-digit earnings growth persisting. With the possibility of a P/E expansion adding to future return prospects, UNH is certainly a stock worth your next $1000.</p>
<div class="lb-trans"><p>隨着 UNH 的增長保持強勁，股價滯後，股票的估值已經壓縮至相當有吸引力的水平。以今年預期調整後每股收益的 17.4 倍交易，我相信 UNH 股票提供了安全性和上行潛力的強大組合，特別是隨着雙位數盈利增長的持續。隨着 P/E 擴張可能增加未來回報前景，UNH 股票絕對是值得您下一個 1000 美元投資的股票。</p>
</div><p><em>On the date of publication, Nikolaos Sismanis did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.</em></p>
<div class="lb-trans"><p><em>在發佈日期，Nikolaos Sismanis 沒有持有（直接或間接）本文提到的證券中的任何頭寸。本文中表達的觀點屬於作者，遵守 InvestorPlace.com 的發佈準則。</em></p>
</div><p>Nikolaos Sismanis is a professional research analyst with five years of experience in the field of equity research and financial modeling. Nikolaos has authored over 1,000 stock-related articles that focus on uncovering deep value opportunities, identifying growth stocks at reasonable valuations, and shining a spotlight on overlooked international equities.</p>
<div class="lb-trans"><p>Nikolaos Sismanis 是一位專業的研究分析師，在股票研究和財務建模領域擁有五年的經驗。Nikolaos 撰寫了超過 1,000 篇與股票相關的文章，專注於發掘深度價值機會，識別合理估值的成長股，並關注被忽視的國際股票。</p>
</div>

現在用 1000 美元購買的三隻最明智的道瓊斯股票